Trial site
Centre Hospitalier Blois Simone Veil
Blois Cedex, 41016, FranceNot linked to an institution yet
- 17running trials
- 1closed trial
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 24 trials
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Recruiting8 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- UNICANCER5 trials
- Intergroupe Francophone du Myelome2 trials
- Novartis Pharmaceuticals2 trials
- Assistance Publique - Hôpitaux de Paris1 trial
- Assistance Publique Hopitaux De Paris1 trial
- and 7 more
Running trials
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· Phase 2· UNICANCER· Source
Recruiting
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· Phase 3· UNICANCER· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· Phase 3· GlaxoSmithKline· Source
Recruiting
Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastatique non résécable : étude de phase 3 randomisée multicentrique en double aveugle.
2023-507873-16-00· Phase 4· Centre Hospitalier Regional Universitaire De Tours· Source
Recruiting
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
NCT06561854· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
UVB: treatment of UVeitis in Behçet’s diseases with biologic
2024-513371-41-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· Phase 2· Unicancer· Source
Active, not recruiting
MInimal Residual Disease Adapted Strategy
NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source
Active, not recruiting
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
NCT04751877· Phase 3· Poitiers University Hospital· Source
Completed
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
NCT02967289· Phase 3· UNICANCER· Source
Completed
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· Phase 3· UNICANCER· Source
Active, not recruiting
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
NCT02355379· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Active, not recruiting
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
NCT01805271· Phase 3· UNICANCER· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error